- Home
- PBF vs AKRO Comparison
PBF vs AKRO Comparison
Compare PBF & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBF
- AKRO
- Stock Information
- Founded
- PBF 2008
- AKRO 2017
- Country
- PBF United States
- AKRO United States
- Employees
- PBF N/A
- AKRO N/A
- Industry
- PBF Integrated oil Companies
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PBF Energy
- AKRO Health Care
- Exchange
- PBF Nasdaq
- AKRO Nasdaq
- Market Cap
- PBF 3.3B
- AKRO 3.6B
- IPO Year
- PBF 2012
- AKRO 2019
- Fundamental
- Price
- PBF $27.96
- AKRO $44.03
- Analyst Decision
- PBF Hold
- AKRO Strong Buy
- Analyst Count
- PBF 14
- AKRO 8
- Target Price
- PBF $26.14
- AKRO $80.38
- AVG Volume (30 Days)
- PBF 3.9M
- AKRO 923.5K
- Earning Date
- PBF 10-30-2025
- AKRO 11-07-2025
- Dividend Yield
- PBF 3.84%
- AKRO N/A
- EPS Growth
- PBF N/A
- AKRO N/A
- EPS
- PBF N/A
- AKRO N/A
- Revenue
- PBF $30,275,300,000.00
- AKRO N/A
- Revenue This Year
- PBF N/A
- AKRO N/A
- Revenue Next Year
- PBF $5.91
- AKRO N/A
- P/E Ratio
- PBF N/A
- AKRO N/A
- Revenue Growth
- PBF N/A
- AKRO N/A
- 52 Week Low
- PBF $13.62
- AKRO $21.34
- 52 Week High
- PBF $34.31
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- PBF 57.56
- AKRO 39.02
- Support Level
- PBF $27.53
- AKRO $42.56
- Resistance Level
- PBF $31.06
- AKRO $46.18
- Average True Range (ATR)
- PBF 1.59
- AKRO 1.75
- MACD
- PBF 0.14
- AKRO -0.14
- Stochastic Oscillator
- PBF 54.00
- AKRO 24.46
About PBF PBF Energy Inc.
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines and storage facilities. The Logistics segment consists solely of PBFX's operations.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.